Pregnancy outcomes following exposure to abatacept during pregnancy  by Kumar, Monica et al.
Seminars in Arthritis and Rheumatism 45 (2015) 351–356Contents lists available at ScienceDirectSeminars in Arthritis and Rheumatismhttp://d
0049-01
(http://c
Abbre
Drug Ad
MMF, m
OTIS, O
RCT, ran
This s
Comp
ees and
and sto
n Corr
E-m
1 Pjournal homepage: www.elsevier.com/locate/semarthritPregnancy outcomes following exposure to abatacept
during pregnancy
Monica Kumar, MD, MPHa,1, Laura Ray, RNa, Sudha Vemuri, PhDb, Teresa A. Simon, MPHa,n
a Bristol-Myers Squibb, Princeton, NJ
b Bristol-Myers Squibb, Plainsboro, NJa r t i c l e i n f o
Keywords:
Pregnancy
Abatacept
Exposure
Congenital anomalies
Biological disease-modifying antirheumatic
drugsx.doi.org/10.1016/j.semarthrit.2015.06.016
72/& 2015 The Authors. Published by Elsevie
reativecommons.org/licenses/by-nc-nd/4.0/).
viations: DMARD, disease-modifying antirheu
ministration; MADCF, Metropolitan Atlanta
ycophenolate mofetil; MMS, mycophenolate
rganization of Teratology Information Speciali
domized controlled trial; TNF, tumor necro
tudy was sponsored by Bristol-Myers Squibb
eting interests: Laura Ray, Sudha Vemuri, and
stockholders of Bristol-Myers Squibb. Monica
ckholder of Bristol-Myers Squibb and current
espondence to: 311 Pennington Rocky Hill Rd
ail address: Teresa.Simon@bms.com (T.A. Sim
resent address: Sanoﬁ US, Bridgewater, NJ.a b s t r a c t
Objective: To characterize pregnancy outcomes following maternal and paternal exposure to abatacept,
using clinical trial and post-marketing data available to the manufacturer.
Methods: All conﬁrmed cases of pregnancy with outcome data reported to the manufacturer up to
September 1, 2014 were included. Sources included clinical trials, spontaneously reported (unsolicited)
post-marketing cases, and the Organization of Teratology Information Specialists registry. Details
recorded included number of live births, spontaneous abortions and terminations, pregnancy compli-
cations, and congenital anomalies.
Results: A total of 161 pregnancies with known outcomes were identiﬁed between 1995 and September
2014: 151 were following maternal exposure to abatacept and 10 were following paternal exposure.
Seven of 86 (8.1%) live births following maternal exposure had congenital anomalies (cleft lip/cleft palate,
congenital aortic anomaly, meningocele, pyloric stenosis, skull malformation, ventricular septal defect/
congenital arterial malformation, and Down's syndrome with premature rupture of membranes at 17
weeks that resulted in a live birth via cesarean section and subsequent infant death). In addition, 59 of
the 151 (39.0%) cases with maternal exposure resulted in abortions (40 spontaneous and 19 elective). Of
the 10 pregnancies with paternal exposure, there were nine live births and one elective abortion, with no
congenital abnormalities identiﬁed and no fetal deaths.
Conclusions: Based on these data, there does not appear to be a pattern of congenital anomalies
following maternal or paternal exposure to abatacept. No cases of vertebral defects, anal atresia, cardiac
defects, tracheo-esophageal ﬁstula, renal anomalies, or limb abnormalities (VACTERL) were noted.
Spontaneous abortion rates were within expected range. Abatacept should be used during pregnancy
only if the potential beneﬁt to the mother justiﬁes the potential risk to the fetus.
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Inadvertent exposure to medications during pregnancy is of
concern to both patients and their healthcare providers, partic-
ularly since approximately 50% of pregnancies are unplanned [1].
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on).medications to manage chronic conditions such as autoimmune
diseases. Autoimmune diseases such as rheumatoid arthritis (RA)
disproportionately affect women, including those of childbearing
potential. Non-biologic and biologic disease-modifying antirheu-
matic drugs (DMARDs) that are used to treat these diseases act by
directly modifying immunological pathways involved in the dis-
ease pathology [2–4]. Unintentional exposure to these drugs may
easily occur in cases of unplanned pregnancy, and patients and
rheumatologists need information regarding the use of drugs
during pregnancy and lactation. Some drugs can cross the pla-
centa, depending on the treatment and trimester [4–9]. On the
other hand, uncontrolled inﬂammation adversely affecting the
mother, such as that caused by RA, will create a hostile environ-
ment for the fetus [5,10]. In addition, patients with higher RA
disease activity are at an increased risk of pregnancy loss, preterm
labor, and low birth-weight babies [5,9–11]. The physician and
pregnant patient must balance the potential beneﬁts of DMARDsaccess article under the CC BY-NC-ND license
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fetus, using all available nonclinical and clinical data to make an
informed decision.
There is limited information on exposure to DMARDs during
conception, pregnancy, and lactation [5,6,12]. To help differentiate
potential risk, the US Food and Drug Administration (FDA) pre-
viously classiﬁed medications into ﬁve pregnancy categories (A–D,
X, with a separate designation N for those medications that are not
categorized) based on available nonclinical and clinical data to
indicate the potential of a drug to cause birth defects if used during
pregnancy [13]. However, since this classiﬁcation system has
acknowledged imperfections, the FDA has released new guidance
regarding labeling of products with regard to use during preg-
nancy and lactation. These labeling changes are designed to help
improve the communication of this beneﬁt–risk assessment.
Beginning in June 2015, the ﬁve pregnancy categories will no
longer be used; all newly approved drugs and biologic products
will adhere to the new labeling rule, which will include a summary
of the risks of using a drug during pregnancy and lactation, a
discussion of the supporting data, and information to help health-
care providers make prescribing decisions and counsel women
about the use of drugs during pregnancy and lactation [14]. The
new labeling will be phased in gradually for currently approved
drugs and biologic products.
Most of the current knowledge regarding the safety of DMARD
use during pregnancy is based on observations from unplanned
pregnancies while receiving the drug [5,7,15]. Based on currently
available evidence, DMARDs have been classiﬁed into several
different FDA categories. For example, the non-biological DMARDs
methotrexate (MTX) and leﬂunomide (both FDA category X) are
known to cause fetal death or teratogenic effects and must be
withdrawn prior to planned pregnancy [8,16]. Mycophenolate
mofetil (MMF) or mycophenolate sodium (MMS) (FDA category
D) are associated with increased risk of congenital anomalies and
pregnancy loss in the ﬁrst trimester [17–19]. On the other hand,
the biologic DMARDs including tumor necrosis factor (TNF) inhib-
itors such as adalimumab, etanercept, certolizumab pegol, goli-
mumab, and inﬂiximab (all FDA category B), have no recorded
teratogenic effects in animal studies but are still lacking adequate
human pregnancy safety data. Observational studies have shown
that 12–20% of patients with RA receive TNF-inhibitor therapy
throughout pregnancy [6,20]. Data from these studies have shown
no increase in the risk of adverse pregnancy or fetal outcomes
from exposure to TNF inhibitors in pregnancy [4,5,7,21,22],
although there is insufﬁcient evidence to prove absolute safety
[23]. Limited clinical data are available on the use of other biologic
DMARDs, including rituximab (FDA category C), anakinra (B),
tocilizumab (C), and abatacept (C), during pregnancy [4–
7,22,24,25].
Abatacept is a selective T-cell costimulation modulator
approved in multiple countries for the treatment of RA. It is a
soluble fusion protein that consists of the extracellular domain of
human cytotoxic T lymphocyte-associated antigen 4 linked to the
modiﬁed Fc portion of human immunoglobulin G1. In animal
studies, abatacept crossed the placenta (maternal sera concentra-
tions 1.7–2.4 times higher than fetal sera concentrations) but was
not found to be teratogenic in mice, rats, or rabbits at approx-
imately 29 times exposure associated with maximum recom-
mended human dose ([26] and data on ﬁle). However, only
limited data are available regarding pregnancy outcomes in
humans treated with abatacept [24]. As there are no adequate
and well-controlled studies of abatacept use in pregnant women,
the prescribing information states that abatacept should be used
during pregnancy only if the potential beneﬁt to the mother
justiﬁes the potential risk to the fetus [26].In this report, we present a descriptive analysis of known
pregnancy outcomes following maternal and paternal exposure
to abatacept, using clinical trial, spontaneous post-marketing
reports, and registry data.Methods
Patient population included in the analysis
Pregnancy outcomes were evaluated in female or male patients
exposed to abatacept. All medically conﬁrmed cases of pregnancy
with outcome data reported to the manufacturer from initial phase
1 studies commenced in 1995 to September 1, 2014 were included
in the study.
In the randomized controlled trials (RCTs), all patients were
required to have been on a background DMARD regimen (54%
received MTX). Women of childbearing potential enrolled in the
clinical trials had to undergo a pregnancy test at every visit prior to
abatacept treatment; thus, there were monthly pregnancy tests
during the blinded phase of the studies. Moreover, women of
childbearing potential who were unwilling or unable to use an
acceptable method of contraception for the entire study period
and for up to 10 weeks after the last dose of investigational
product were excluded from the trials, as were women who were
pregnant or breastfeeding and those with a positive pregnancy test
result on enrollment or before administration of an investigational
drug. Patients found to be pregnant during the study were with-
drawn from the trial and abatacept was discontinued.Data collection
Data on pregnancy outcomes following maternal or paternal
exposure were obtained from the Bristol-Myers Squibb safety
database that includes clinical trial data (prospective) and post-
marketing reports (prospective and retrospective data). The safety
database was searched for all reports of pregnancy from 1995 to
2014. Post-marketing data were obtained from spontaneous case
reports submitted to the relevant regulatory health authorities,
direct reporting of exposure from individuals and healthcare
providers, phase 4 studies, and the Organization of Teratology
Information Specialists (OTIS) registry (ongoing autoimmune dis-
eases in pregnancy study, http://www.pregnancystudies.org/
ongoing-pregnancy-studies/autoimmune-studies/). OTIS collects
health information from women who take medicines or vaccines
during pregnancy, and provides evidence-based information to
healthcare professionals and the general public about medications
and other exposures during pregnancy and breastfeeding. Partic-
ipants were enrolled after contacting OTIS and subsequently
interviewed and asked about their health history, pregnancy, and
the birth. The OTIS study is approved by the Institutional Review
Board of the University of California, San Diego.
Details recorded included the number of live births, sponta-
neous abortions, and terminations. In addition, details of preg-
nancy complications and of any congenital abnormalities were
recorded. Congenital anomalies were identiﬁed using the Centers
for Disease Control and Prevention's Metropolitan Atlanta Con-
genital Defects Program (MACDP; version 08/07; http://www.cdc.
gov/ncbddd/birthdefects/MACDP.html), which is a population-
based active surveillance system for birth defects. For pregnancy
cases from clinical trials, follow-up was as follows: two attempts
for initial reports of pregnancy, three attempts to obtain outcome,
and two additional attempts for follow-up as appropriate.
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Patient demographics and distribution of cases
A total of 161 discrete pregnancies with known outcomes were
identiﬁed; 100 cases were reported before the outcome occurred
(prospectively) and the remaining 61 were reported after the
outcome occurred (retrospectively). Maternal exposure to abata-
cept occurred in 151 cases and 10 cases were following paternal
exposure.
For both clinical trials and spontaneous post-marketing case
reports, approximately 50% of cases were reported from the USA,
Mexico, Canada, or Argentina. All other cases were reported from
South America, Europe, South Africa, or East Asia.
Maternal exposures
Of the 151 maternal exposure pregnancies with known out-
comes, 68 were from the clinical trials, 80 were reported as post-
marketing reports, and three were from the ongoing OTIS registry.
The mean (range) maternal age of patients in the clinical trials was
30.1 (15–44) years, and 31.2 years in post-marketing/spontaneous
case reports. Relevant medical history and concomitant medica-
tions are presented in Table 1.
Pregnancy outcomes
The outcomes of pregnancies with maternal exposure (n ¼ 151)
to abatacept overall and stratiﬁed by clinical trials and post-
marketing reports are reported in Table 2. Seven MACDP-
identiﬁed congenital anomalies were recorded among the 86 live
births; one of the seven was Down's syndrome that resulted in
infant death at birth following a premature rupture of membranes.
Overall, 40 spontaneous abortions, including a late abortion at
approximately 21 weeks of gestation, occurred and 19 elective
terminations were performed.
Reported anomalies
The identiﬁed congenital anomalies included cleft lip/cleft
palate, congenital aortic anomaly, meningocele, pyloric stenosis,
skull malformation, ventricular septal defect/congenital arterial
malformation, and Down's syndrome with premature rupture of
membranes at 17 weeks that resulted in a live birth via cesarean
section and subsequent infant death. Reported anomalies were
identiﬁed from OTIS (3/7) and post-marketing/unprompted
reports (4/7); no anomalies were seen in the live births that
occurred in the clinical trials. Pregnancy details and maternal
medical histories for the congenital anomalies reported in the OTISTable 1
Maternal demographic characteristics in pregnancies with known outcomes
Patient characteristica RCT Post-marketing
and spontaneous
case reports
OTIS
registry
n 68 80 3
Mean age, years 30.1 31.2 32.7
History of diabetes, n
Pre-gestational 1 3 1
Gestational 4 1 –
Drug discontinuation, % 100 100 100
OTIS, Organization of Teratology Information Specialists; RCT, randomized
controlled trial.
a For cases where information was available.registry and post-marketing reports are detailed in Table 3. Most of
the exposures associated with congenital anomalies occurred in
the ﬁrst trimester and were reported in patients who took
concomitant medications of category D or X, including leﬂuno-
mide, MTX, MMF, and MMS. Table 2 summarizes the details for
abortions and fetal deaths that occurred following maternal
exposure to abatacept; the majority of spontaneous abortions in
the clinical trials (13 out of 17) occurred within the ﬁrst 10 weeks.
Notably, 20/40 of all patients (50%) who experienced spontaneous
abortions received concomitant MTX, including 12/17 patients
(70.6%) in the clinical trials.Fetal deaths
Four of the pregnancies resulted in fetal death, with limited
information available. Details available on the four cases are
listed below: (1) intrauterine fetal death due to an unknown
cause occurred at approximately 24 weeks of gestation and the
pregnancy was terminated via cesarean section, (2) during the
pregnancy with diagnosed Down's syndrome, the patient expe-
rienced a premature rupture of membranes at 17 weeks of
gestation that resulted in a live birth via cesarean section and
subsequent infant death, (3) death occurred at or shortly after
delivery (at term) following a grade IV hemorrhagic stroke, and
(4) the ﬁnal case of fetal death occurred at approximately 15
weeks of gestation and was possibly related to maternal
toxoplasmosis.
Postnatal follow-up
Postnatal follow-up to 1 year was available for 16 cases in the
RCTs. Length of follow-up ranged from 6 to 49 weeks. None of the
infants for whom postnatal follow-up was available were diag-
nosed with anomalies after birth, and no immune deﬁciencies
were reported.
Paternal exposures
Of the 10 pregnancies with paternal exposure to abatacept,
there were nine live births and one elective abortion, with no
congenital abnormalities identiﬁed and no fetal deaths (data not
shown). Six of the cases were reported prospectively and four were
retrospective. Among the nine live births following paternal
exposure, reported concomitant medications of category D or
above were MTX (n ¼ 3), leﬂunomide (n ¼ 1), and MMF/MMS
(n ¼ 1).Discussion
Pregnancy alters autoimmune disease pathophysiology
and drug metabolism, and both the disease and its treatment
can have unpredictable effects on the unborn child [5]. Studies
to date have shown no increased risk of adverse pregnancy or
fetal outcomes from exposure to TNF inhibitors during
pregnancy [4,5,7,21,22]; however, there is a paucity of data
available on use of other biologic DMARDs during pregnancy
[4–7,22,24,25].
Here, we report for the ﬁrst time pregnancy outcomes with
abatacept exposure. A total of 161 pregnancies with known out-
comes were identiﬁed, including 151 with maternal exposure to
abatacept and 10 with paternal exposure. In the 86 live births
following maternal abatacept exposure, seven (8.1%) MACDP-
identiﬁed congenital anomalies were recorded. No cases of verte-
bral defects, anal atresia, cardiac defects, tracheo-esophageal
Table 2
Overview of pregnancy outcomes with maternal exposure to abatacept
Outcomes Count, n RCT Post-marketing and
unprompted case reports
OTIS registry
N ¼ 151 n ¼ 68 n ¼ 80 n ¼ 3
Total live births, n (%) 86 (60.0) 35 (51.5) 48 (60.0) 3 (100)
Congenital anomaliesa, n (%) 7 (8.1) – 4 (5.0) 3 (100)
Cleft lip/cleft palate 1 – – 1
Down's syndrome 1 – 1 –
Congenital aortic anomaly 1 – 1 –
Meningocele 1 – 1 –
Pyloric stenosis 1 – – 1
Skull malformation 1 – 1 –
Ventricular septal defect;
congenital arterial malformation
1 – – 1
Abortion, n
Spontaneous, n (%) 40 (26.5) 17 (25.0) 23 (29.0)
Age, mean (range), yearsb 31.9 (17–44) 32.9 (20–44) 31.1 (17–41)
Concomitant methotrexate, nb 20 12 8
Timing, nb
r10 weeks 15 – 2
r6 weeks 9 9 –
7–10 weeks 4 4 –
First trimesterc 6 2 4
Unknown 19 2 17
Type 1 diabetes, n 1 – 1
Elective, n (%) 18 (12.0) 12 (17.6) 6 (7.5)
Late 1 1 –
Fetal death, n (%)d 4 2 2 –
OTIS, Organization of Teratology Information Specialists; RCT, randomized controlled trial.
a Six of the seven are included in the live births category.
b Where information was available.
c Exact date not provided.
d Fetal death was deﬁned as intrauterine death of a fetus 420 weeks of gestation.
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noted. The available data for abatacept presented here do not
appear to show a pattern of congenital anomalies following
maternal or paternal exposure. In addition, 59 of the 151 pregnan-
cies resulted in abortions (40 spontaneous and 19 elective). WhereTable 3
Pregnancy details for the observed congenital abnormalities
Observed congenital
anomalies
Number, n Retrospectively
reported
Maternal
age, years
Maternal
race
OTIS registry
Cleft lip/cleft palate 1 Y 36 Black
Pyloric stenosis 1 Y 25 White
Ventricular septal
defect and congenital
arterial malformation
1 Y 37 Unknown
Post-marketing and unprompted case reports
Down's syndromeb 1 Y 28 Unknown
Congenital aortic
anomaly
1 N 27 White
Meningocele 1 Y Unknown Unknown
Skull malformation 1 N 31 White
FDA, Food and Drug Administration; n/a, not available; OTIS, Organization of Teratology
a Only concomitant medications that are FDA pregnancy category D or higher in th
b Resulted in fetal death.data were available regarding concomitant medications, MTX was
the most common reported agent.
The management of patients with RA wishing to conceive
involves adaptation of treatment to keep disease controlled, but
pregnant women should not receive teratogenic drugs such asTime of
exposure
Exposure to
concomitant
medicationsa
Maternal medical history Country
First trimester – Type 2 diabetes USA
First trimester – Hypertension, depression/
anxiety, ﬁbromyalgia,
and hypothyroidism
USA
First trimester Leﬂunomide Hypothyroidism USA
Unknown – n/a Argentina
First trimester – Type 1 diabetes USA
Unknown Mycophenolate
mofetil
Mycophenolate
sodium
n/a France
First trimester – n/a Belgium
Information Specialists.
e USA are listed.
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conceive, and time to conception is longer in those with higher
disease activity [27]. In addition, patients with RA are more likely
to have preterm births [28]. Elevated disease activity during
pregnancy is associated with rapid postnatal catch-up growth
in offspring, a risk factor for cardiovascular disease in adulthood
[29]. In patients treated with MTX, pregnancy losses of approx-
imately 42% are seen, with twice as many birth defects noted
compared with non-treated patients [30]. Verstappen et al. [31]
reported that the rate of spontaneous abortion was highest (27%)
in patients exposed to anti-TNFs during pregnancy at the
time of conception. The rate of spontaneous abortion in our data
set was 25.8% overall and similar to the published rate of
spontaneous abortions, if clinically undetectable pregnancies
are included [31,32]. Half of the patients who experienced
spontaneous abortions received concomitant MTX. Furthermore,
the incidence of early miscarriage is unknown for women with
autoimmune diseases [31]. In addition, the increased rate of
spontaneous abortions observed may in part be due to detection
bias: clinical trials are closely monitored and approximately 50%
of the spontaneous abortions identiﬁed in the RCT data were
identiﬁed early (o6 weeks) and may not have been identiﬁed or
clinically detected if the patients had not been enrolled in a
clinical trial.
This study reports data from a small number of patients with
maternal pregnancy outcomes, of which 45% were obtained
from post-marketing and spontaneous sources. Although those
sources are effective and valuable in capturing data, there are
many limitations of the data that may make them difﬁcult to
interpret and limit the ability to generalize them. The treated
patients in these reports may have had greater disease
severity, comorbidities may have been unknown, no denomina-
tor for comparison was available, and data were often
recorded incompletely and/or inconsistently [5]. In addition,
the data were mostly retrospective, which usually are negatively
biased and subject to recall with limited follow-up. These study
limitations and the effect of RA on pregnancy may account for
the number of MACDP-identiﬁed congenital anomalies (8.1%)
being slightly greater that that seen in the general population
(3–5%).
Bristol-Myers Squibb continues to monitor and collect infor-
mation on the outcomes of abatacept-exposed pregnancies in an
ongoing study using the OTIS Research Group as an integrated
project within the existing OTIS Autoimmune Diseases in Preg-
nancy Project [33]. This prospective, observational, cohort study of
women exposed to abatacept will continue data collection for the
next several years. However, the long-term effects of abatacept on
the developing immune system are presently not known and
abatacept should be used during pregnancy only if the potential
beneﬁt to the mother justiﬁes the potential risk to the fetus.
Therefore, patients of childbearing potential with RA who are
being treated with DMARDs require counseling with regard to
pregnancy outcomes [6,34].Acknowledgments
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